New drug combo shows promise in early cancer trial
NCT ID NCT03486301
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is complete, but results are not yet widely available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BDB001 (an immunotherapy drug) and pembrolizumab (a drug that helps the immune system fight cancer)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is an early Phase 1 trial with only 87 participants, focused on safety and dosing. It is too small and early to know if the combination will be effective or safe for broader use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlantic Health
Morristown, New Jersey, 07960, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34230, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States